Trinity Biotech appoints Jerry Lydon to lead North America commercial operations amid transformation progress

Trinity Biotech has appointed Jerry Lydon as Head of North America Commercial Operations to drive revenue growth and profitability following its Comprehensive Transformation Plan. The company reported Q4 2025 revenues of $11.1 million with improved gross margins, despite a year-on-year revenue decline due to market disruptions and manufacturing adjustments. Lydon will oversee commercial execution, including new product launches like EpiCapture and PrePsia, supporting the company’s focus on operational efficiency and innovation. Trinity continues to scale outsourced manufacturing and aims for sustainable financial improvements in its core diagnostics business.